Research & Development

Citius raises $36.5m for Lymphir commercialisation

Citius Oncology has secured up to $36.5m in a combination of debt and equity financing to accelerate the commercialisation of Lymphir (denileukin diftitox-cxdl), a recombinant fusion protein immune therapy.

MSD concludes Terns acquisition to expand CML pipeline

Merck & Co (MSD) has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML).

Latus Bio secures $97m in funding to boost gene therapy access

Latus Bio has closed a $97m Series A financing round to expand the reach of its gene therapies to wider patient groups.

LEO Pharma to acquire gene therapy company Replay

LEO Pharma has signed a definitive agreement for the acquisition of Replay, a gene therapy company that develops treatments for rare genetic dermatological conditions.

Ray Therapeutics receives EMA PRIME status for gene therapy

Ray Therapeutics has received priority medicines (PRIME) designation from the European Medicines Agency (EMA) for its RTx-015 gene therapy to treat retinitis pigmentosa (RP).

Arcera and Fosun sign MoU for neuroscience innovation

Arcera Life Sciences and Fosun Pharma have signed a memorandum of understanding (MoU) for a strategic long-term collaboration in licensing, technology, and neuroscience innovation in the global life sciences industry.

Rocket to sell PRV for $180m to advance gene therapy pipeline

Rocket Pharmaceuticals has signed an agreement to sell its rare paediatric disease priority review voucher (PRV) for $180m to advance its gene therapy pipeline.

BioMarin acquires Amicus Therapeutics for $4.8bn

BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal for a total equity value of nearly $4.8bn.

Sun Pharma to acquire Organon for $11.75bn

Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon in a transaction with an enterprise valuation of $11.75bn in cash, paying $14.00 per share for all outstanding shares.